Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Price:
38.28 USD
0.34%
Market Closed
Updated:
Apr 29, 2024
Rhythm Pharmaceuticals Inc
Cash from Financing Activities
|
Rhythm Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
|
Cash from Financing Activities
$74.4m
|
CAGR 3-Years
233%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Rhythm Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
74.4m
USD
74.4m
USD
Based on the financial report for Dec 31, 2023, Rhythm Pharmaceuticals Inc's Cash from Financing Activities amounts to 74.4m USD.
What is Rhythm Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-15%
-15%
Over the last year, the Cash from Financing Activities growth was -65%. The average annual Cash from Financing Activities growth rates for Rhythm Pharmaceuticals Inc have been 233% over the past three years , -15% over the past five years .
You don't have any saved screeners yet
